MCID: PTT008
MIFTS: 45

Pituitary Carcinoma malady

Categories: Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Pituitary Carcinoma

Aliases & Descriptions for Pituitary Carcinoma:

Name: Pituitary Carcinoma 12 50 56 14 69
Malignant Neoplasm of Pituitary Gland 69
Carcinoma of the Pituitary Gland 12
Pituitary Cancer 50

Characteristics:

Orphanet epidemiological data:

56
pituitary carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:4916
MeSH 42 D010911
NCIt 47 C4536
SNOMED-CT 64 128665000 254955001
Orphanet 56 ORPHA300385
UMLS via Orphanet 70 C0346300
ICD10 via Orphanet 34 C75.1
ICD10 33 C75.1
UMLS 69 C0346300

Summaries for Pituitary Carcinoma

MalaCards based summary : Pituitary Carcinoma, also known as malignant neoplasm of pituitary gland, is related to prolactin producing pituitary tumor and hormone producing pituitary cancer, and has symptoms including ataxia, headache and hearing impairment. An important gene associated with Pituitary Carcinoma is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Menthol and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, spinal cord and liver.

Related Diseases for Pituitary Carcinoma

Diseases related to Pituitary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
id Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 31.3 CHGA MUC1
2 hormone producing pituitary cancer 11.8
3 burning mouth syndrome type 3 10.3 POMC SST
4 renal hypoplasia, bilateral 10.3 POMC SST
5 water-clear cell adenoma 10.2 POMC SST
6 vaginal adenoma 10.2 POMC SST
7 african histoplasmosis 10.2 POMC SST
8 extragonadal nonseminomatous germ cell tumor 10.2 POMC SST
9 protein s deficiency 10.2 POMC SST
10 parietal lobe neoplasm 10.2 CHGA POMC
11 secondary syphilis 10.2 CHGA SST
12 brain edema 10.2 CHGA SST
13 syringomelia hyperkeratosis 10.2 CHGA POMC
14 oculocutaneous albinism 10.2 CHGA SST
15 gmppa-cdg 10.2 CHGA SST
16 volkmann contracture 10.2 CHGA SST
17 adult botryoid rhabdomyosarcoma 10.2 CHGA SST
18 spinal stenosis 10.2 CHGA SST
19 intermittent squint 10.2 CRH POMC
20 progressive relapsing multiple sclerosis 10.2 CHGA SST
21 dacryoadenitis 10.2 CRH POMC
22 hypogonadism cardiomyopathy 10.2 CRH POMC
23 cowden syndrome 3 10.2 CHGA SST
24 rheumatic encephalitis 10.2 POMC SST
25 femur bifid with monodactylous ectrodactyly 10.2 CRH POMC
26 acute pyelonephritis 10.2 CHGA SST
27 maturity-onset diabetes of the young, type 13 10.2 CHGA SST
28 cardioauditory syndrome of sanchez cascos 10.2 CHGA SST
29 keloids 10.2 CHGA SST
30 malignant otitis externa 10.2 CRH POMC
31 sternum lymphoma 10.2 CHGA POMC
32 neurogenic arthropathy 10.2 POMC SST
33 myoepithelial carcinoma 10.2 CHGA SST
34 autoimmune disease of endocrine system 10.2 CRH POMC
35 traumatic glaucoma 10.2 CRH POMC
36 peeling skin syndrome 10.2 CHGA POMC
37 astroblastoma 10.2 CRH POMC
38 bile acid synthesis defect, congenital, 4 10.1 POMC SST
39 ascariasis 10.1 SST SSTR2
40 neuritis 10.1 SST SSTR2
41 uterine ligament cancer 10.1 SST SSTR2
42 adult i blood group with or without congenital cataract 10.1 CRH POMC
43 hepatitis b reinfection following liver transplantation 10.1 CHGA SST
44 chondroma 10.1 POMC SST
45 childhood optic tract astrocytoma 10.1 CRH POMC
46 fatty liver disease 10.1 CRH POMC
47 tuberculous peritonitis 10.1 CHGA CRH
48 ampulla of vater mucinous adenocarcinoma 10.1 CHGA SSTR2
49 acute gonococcal salpingitis 10.1 CRH POMC
50 cervical alveolar soft part sarcoma 10.1 SST SSTR2

Graphical network of the top 20 diseases related to Pituitary Carcinoma:



Diseases related to Pituitary Carcinoma

Symptoms & Phenotypes for Pituitary Carcinoma

Human phenotypes related to Pituitary Carcinoma:

56 32 (show all 24)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 56 32 Occasional (29-5%) HP:0001251
2 headache 56 32 Very frequent (99-80%) HP:0002315
3 hearing impairment 56 32 Occasional (29-5%) HP:0000365
4 diabetes insipidus 56 32 Very rare (<4-1%) HP:0000873
5 growth hormone excess 56 32 Occasional (29-5%) HP:0000845
6 pituitary prolactin cell adenoma 56 32 Very frequent (99-80%) HP:0006767
7 pituitary growth hormone cell adenoma 56 32 Occasional (29-5%) HP:0011760
8 pituitary corticotropic cell adenoma 56 32 Very frequent (99-80%) HP:0008291
9 increased circulating acth level 56 32 Very frequent (99-80%) HP:0003154
10 prolactin excess 56 32 Very frequent (99-80%) HP:0000870
11 pituitary carcinoma 56 32 Obligate (100%) HP:0011763
12 spinal cord lesion 56 32 Occasional (29-5%) HP:0100561
13 hypopituitarism 56 32 Frequent (79-30%) HP:0040075
14 progressive visual field defects 56 32 Frequent (79-30%) HP:0007987
15 malignant neoplasm of the central nervous system 56 32 Very frequent (99-80%) HP:0100836
16 enlarged pituitary gland 56 32 Frequent (79-30%) HP:0012505
17 pituitary gonadotropic cell adenoma 56 32 Very rare (<4-1%) HP:0011759
18 pituitary thyrotropic cell adenoma 56 32 Very rare (<4-1%) HP:0011762
19 reduced visual acuity 32 HP:0007663
20 hemianopsia 56 Frequent (79-30%)
21 mildly reduced visual acuity 56 Frequent (79-30%)
22 hyperpituitarism 56 Occasional (29-5%)
23 abnormality of central motor function 56 Occasional (29-5%)
24 hemianopia 32 HP:0012377

Drugs & Therapeutics for Pituitary Carcinoma

Drugs for Pituitary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
3
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
4
Cabergoline Approved Phase 4,Phase 2,Phase 3,Early Phase 1 81409-90-7 54746
5
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
11
lanreotide Approved Phase 4,Phase 3 108736-35-2
12
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
13
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
14
Progesterone Approved, Vet_approved Phase 4,Phase 1,Phase 2 57-83-0 5994
15
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
16
Cefazolin Approved Phase 4 25953-19-9 656510 33255
17
Cefdinir Approved Phase 4 91832-40-5 6915944
18
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
19
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
23
Liraglutide Approved Phase 4 204656-20-2
24
Metformin Approved Phase 4 657-24-9 14219 4091
25
Zinc Approved Phase 4 7440-66-6 32051 23994
26
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
27
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
28
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
29
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
30
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 54575, 6560146 143
33
Butyric Acid Experimental Phase 4 107-92-6 264
34 Anesthetics Phase 4,Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
37 Cortisol succinate Phase 4,Phase 3,Phase 2
38 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
39 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2
43 Hydrocortisone acetate Phase 4,Phase 3,Phase 2
44 Hydrocortisone-17-butyrate Phase 4
45 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Liver Extracts Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 231)
id Name Status NCT ID Phase
1 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
3 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4
4 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Completed NCT01861717 Phase 4
5 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4
6 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4
7 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
8 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4
9 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4
10 Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study Completed NCT02204826 Phase 4
11 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4
12 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
13 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4
14 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4
15 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4
16 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4
17 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4
18 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4
19 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4
20 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4
21 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
22 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4
23 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4
24 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4
25 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
26 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4
27 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4
28 Polycystic Ovary Syndrome (PCOS) and Sleep Apnea Terminated NCT00203996 Phase 4
29 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3
30 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3
31 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3
32 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3
33 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
34 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3
35 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3
36 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3
37 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3
38 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3
39 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Completed NCT01653743 Phase 3
40 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3
41 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3
42 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3
43 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3
44 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3
45 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3
46 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3
47 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3
48 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3
49 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3
50 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3

Search NIH Clinical Center for Pituitary Carcinoma

Genetic Tests for Pituitary Carcinoma

Anatomical Context for Pituitary Carcinoma

MalaCards organs/tissues related to Pituitary Carcinoma:

39
Pituitary, Spinal Cord, Liver, Lung, Thyroid

Publications for Pituitary Carcinoma

Articles related to Pituitary Carcinoma:

(show top 50) (show all 54)
id Title Authors Year
1
Response of silent corticotroph pituitary carcinoma to chemotherapy: case report. ( 27150544 )
2016
2
Genetic aspects of pituitary carcinoma: A systematic review. ( 27893664 )
2016
3
Temozolomide therapy: Focus on patients with pituitary carcinoma. ( 27365946 )
2016
4
Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions. ( 27157283 )
2016
5
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. ( 27106209 )
2016
6
Secreting Follicle-Stimulating Hormone Pituitary Carcinoma with Cervical Metastasis. ( 27449685 )
2016
7
Pituitary carcinoma with intraspinal metastasis: report of two cases and review of the literature. ( 26464743 )
2015
8
Diagnosis and Treatment of Pituitary Carcinoma. ( 26564466 )
2015
9
Progression of an Invasive ACTH Pituitary Macroadenoma with Cushing's Disease to Pituitary Carcinoma. ( 26366311 )
2015
10
MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. ( 25862551 )
2015
11
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( 25646794 )
2015
12
Drop metastasis of adrenocorticotropic hormone-producing pituitary carcinoma to the cauda equina. ( 25346823 )
2014
13
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma. ( 24823463 )
2014
14
A case report of feline pituitary carcinoma with hypercortisolism. ( 24025433 )
2014
15
Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. ( 24272034 )
2014
16
The Use of 68Ga DOTATATE PET/CT for Diagnostic Assessment and Monitoring of 177Lu DOTATATE Therapy in Pituitary Carcinoma. ( 25275413 )
2014
17
Invasive adenoma and pituitary carcinoma: a SEER database analysis. ( 24526366 )
2014
18
Improvement in Diagnosis of Metastatic Pituitary Carcinoma by 68Ga DOTATATE PET/CT. ( 24873798 )
2014
19
Lesions of the petrous ridge: metastatic pituitary carcinoma with discussion of differential diagnosis. ( 24622018 )
2014
20
Pituitary carcinoma with endolymphatic sac metastasis. ( 23645293 )
2014
21
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. ( 23955641 )
2013
22
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. ( 23365123 )
2013
23
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. ( 24455332 )
2013
24
Pituitary carcinoma in situ. ( 23425649 )
2013
25
Tumor-to-tumor metastasis from pituitary carcinoma to radiation-induced meningioma. ( 22989053 )
2013
26
The significance of MEN1 mutations in pituitary carcinomas. ( 23905891 )
2013
27
Pituitary carcinoma: a devastating disease in need of an earlier diagnosis and of effective therapies. ( 22120355 )
2013
28
Long-term follow-up of growth hormone-producing pituitary carcinoma with multiple spinal metastases following multiple surgeries: case report. ( 24077272 )
2013
29
A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. ( 23091742 )
2012
30
Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: case report. ( 22333938 )
2012
31
What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? ( 23422771 )
2012
32
Metastatic pituitary carcinoma in a patient with acromegaly: a case report. ( 23009369 )
2012
33
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( 22520146 )
2012
34
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( 21389894 )
2011
35
MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. ( 20960104 )
2010
36
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( 20660056 )
2010
37
Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. ( 18755492 )
2009
38
[Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options]. ( 19878763 )
2009
39
Selective chemical rescue of a thyroid-hormone-receptor mutant, TRbeta(H435Y), identified in pituitary carcinoma and resistance to thyroid hormone. ( 18683837 )
2008
40
P53 gene mutations in pituitary carcinomas. ( 18026859 )
2007
41
[Pituitary carcinoma. Anatomic and clinical features of cases reported in literature]. ( 17524431 )
2007
42
Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma. ( 17084204 )
2006
43
Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. ( 16943582 )
2006
44
Pituitary carcinoma: a review of the literature. ( 15191336 )
2004
45
Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. ( 12924717 )
2003
46
Absent p53 immunohistochemical staining in a pituitary carcinoma. ( 11383946 )
2001
47
Chromosomal aberrations in pituitary carcinoma metastases. ( 11563625 )
2001
48
Refractory hypokalemia in metastatic adrenocorticotrophic hormone--secreting pituitary carcinoma. ( 11273189 )
2000
49
Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. ( 9211132 )
1997
50
Pituitary carcinoma: a clinicopathologic study of 15 cases. ( 9024719 )
1997

Variations for Pituitary Carcinoma

Expression for Pituitary Carcinoma

Search GEO for disease gene expression data for Pituitary Carcinoma.

Pathways for Pituitary Carcinoma

GO Terms for Pituitary Carcinoma

Cellular components related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 CHGA CRH MUC1 POMC SST
2 extracellular space GO:0005615 9.02 CHGA CRH MUC1 POMC SST

Biological processes related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.26 CHGA POMC
2 digestion GO:0007586 9.16 SST SSTR2
3 cell-cell signaling GO:0007267 9.13 POMC SST SSTR2
4 hormone-mediated apoptotic signaling pathway GO:0008628 8.62 CRH SST

Molecular functions related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CRH POMC SST

Sources for Pituitary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....